MCLA-128 Helps Metastatic Breast Cancer Patients, First Results of Phase 1/2 Trial Indicate

MCLA-128 Helps Metastatic Breast Cancer Patients, First Results of Phase 1/2 Trial Indicate
Merus' MCLA-128 antibody has helped patients with HER2-positive metastatic breast cancer who failed several lines of HER2 inhibitor therapy, according to initial results of a Phase 1/2 clinical trial. One of the 11 patients achieved a partial response to the treatment that lasted more than eight months. Seven patients' disease became stable -- and in four of the seven it was stable more than five months. The clinical benefit rate of the treatment was 64 percent. This means that 64 percent of patients either responded to treatment or achieved a stable disease for at least 12 weeks. MCLA-128 is a bi-specific antibody that targets both the HER2 and HER3 proteins associated with breast cancer. The Phase 1/2 trial is the first test of the therapy in humans. Merus agreed to present the Phase 1 part of the trial's results at the American Society of Clinical Oncology Annual Meeting in Chicago, June 2-6. Its poster-session presentation is titled "First-in-human phase 1/2 study of MCLA-128, a full length IgG1 bispecific antibody targeting HER2 and HER3: Final phase 1 data and preliminary activity in HER2+ metastatic breast cancer (MBC)." “These clinical results demonstrate that single agent MCLA-128 is active and well tolerated in heavily pretreated metastatic breast cancer patients,” Dr. Josep Tabernero, head of Medical Oncology at Vall d'Hebron University Hospital, said in a press release. “This positions MCLA-128 as a promising agent fo
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.